Pluri (PLUR) Depreciation & Amortization (CF) (2010 - 2025)
Pluri (PLUR) posted quarterly Depreciation & Amortization (CF) of $129000.0 for Q4 2025, up 89.71% year-over-year from $68000.0 in Q4 2024, and down 0.77% quarter-over-quarter from $130000.0 in Q3 2025.
Pluri (PLUR) Depreciation & Amortization (CF) (2010 - 2025) Analysis & Trends
Pluri (PLUR) has reported Depreciation & Amortization (CF) for 16 consecutive years, with $129000.0 the latest figure, recorded in Q4 2025.
- In Q4 2025, Depreciation & Amortization (CF) rose 89.71% year-over-year to $129000.0; the TTM figure through Dec 2025 stood at $412000.0 (up 61.57% YoY), while the FY2025 annual figure was $316000.0, up 24.9% from the prior year.
- Depreciation & Amortization (CF) slipped to $129000.0 in Q4 2025 per PLUR's latest filing, from $130000.0 in the prior quarter.
- Across five years, Depreciation & Amortization (CF) topped out at $339000.0 in Q1 2021 and bottomed at $61000.0 in Q1 2024.
- Historically, Depreciation & Amortization (CF) has averaged $144400.0 across 5 years, with a median of $92500.0 in 2022.
- Annual changes were most pronounced in 2022 — Depreciation & Amortization (CF) sank 70.34% — and 2025, when it jumped 100.0%.
- Pluri's Depreciation & Amortization (CF) stood at $327000.0 in 2021, then tumbled by 70.34% to $97000.0 in 2022, then sank by 34.02% to $64000.0 in 2023, then advanced by 6.25% to $68000.0 in 2024, then soared by 89.71% to $129000.0 in 2025.
- Business Quant data shows PLUR's Depreciation & Amortization (CF) at $129000.0 in Q4 2025, $130000.0 in Q3 2025, and $81000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Depreciation & Amortization (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 56.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 123.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 40.52 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 191.83 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Pluri | 16.21 Mn | 3.72 Mn | 86,000.00 | 129,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 129,000.00 |
| Dec 31, 2025 | 129,000.00 |
| Sep 30, 2025 | 130,000.00 |
| Sep 30, 2025 | 130,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Jun 30, 2025 | 81,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Mar 31, 2025 | 72,000.00 |
| Dec 31, 2024 | 68,000.00 |
| Dec 31, 2024 | 68,000.00 |
| Sep 30, 2024 | 65,000.00 |
| Sep 30, 2024 | 65,000.00 |
| Jun 30, 2024 | 61,000.00 |
| Jun 30, 2024 | 61,000.00 |
| Mar 31, 2024 | 61,000.00 |
| Mar 31, 2024 | 61,000.00 |
| Dec 31, 2023 | 64,000.00 |
| Dec 31, 2023 | 64,000.00 |
| Sep 30, 2023 | 67,000.00 |
| Sep 30, 2023 | 67,000.00 |